The University of Southampton
University of Southampton Institutional Repository

Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection

Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection
Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection

Whilst the benefit of direct-acting antiviral agents (DAAs) in achieving sustained virological response (SVR) is now well-accepted, their impact on liver function, particularly in relation to achievement of SVR, has not been well documented. We studied 2394 patients with chronic HCV infection, 1276 receiving DAAs and 1118 interferon-based therapy. Liver function was assessed by the albumin-bilirubin (ALBI) score or grade. Overall survival according to SVR status and baseline ALBI grade was examined. We also studied time to first decompensation according to ALBI grade, as well as longitudinal changes in ALBI score over time according to SVR. Among the patients receiving DAAs, 89% achieved SVR (Japan = 99%, UK = 78%). Amongst the decompensated patients in the UK cohort, three distinct risk groups according to ALBI grade at baseline were observed. The UK patients receiving DAAs, who had predominantly decompensated disease, showed clear evidence of improvement of liver function detectable within 2 years of the start of treatment, especially in those achieving SVR. These early changes in liver function were very similar to those observed in the first 2-3 years after interferon-based therapy. DAAs improve liver function especially in those with decompensated disease who achieve SVR. Experience with interferon-based therapy suggests that failure to achieve SVR is associated with long-term decline in liver function and, in contrast, patients who do achieve SVR can expect long-term disease improvement and subsequent stabilization of liver function. Our initial analysis suggests that those receiving DAAs are likely, in the long term, to follow a similar course.

ALBI score, direct-acting antivirals, hepatitis C virus, interferon therapy, liver function, sustained virological response
1352-0504
168-176
Johnson, Philip J.
e926deac-dbac-4455-a6ab-57aa8faed6d4
Berhane, Sarah
c01b3772-aacd-4b21-818d-dc4a7cccf7e3
Walker, Alex J.
3dddfe69-6c9c-41a3-a7ca-10287f577312
Gordon, Fiona H.
bf20bbd0-b7ff-4e5e-8948-96b7ecd3d94b
Ryder, Steven D.
ff0ec802-421b-4033-a960-da5fae9c7f45
McPherson, Stuart
cf52d9f4-2bcb-4954-ba16-f12ddc790b45
Sreedharan, Aravamuthan
40600e27-e985-474e-a806-a7e6c0895ade
Ustianowski, Andrew A.
d4a18651-7b8a-44a9-a18d-f64a340dac7b
Agarwal, Kosh
318c0cdd-390b-475d-bf02-323f52b75d7e
Mutimer, David
d67a2cc4-f17d-446d-9167-955177f1c982
Kumada, Takeshi
66bd6e13-4605-430e-9fbd-ae52374587f1
Toyoda, Hidenori
d6ba8630-a837-4554-860b-13f88250b616
Irving, William L.
ed6993df-07a9-4cc1-a859-aa616d644f43
Agarwal, K.
318c0cdd-390b-475d-bf02-323f52b75d7e
Aldersley, M.
72a9c3f4-f70a-477f-82bc-cfb4bf2ae8fe
Ala, A.
6d76aceb-97a9-4581-bc09-7a50a4854aba
Aspinall, R.
455c619f-1968-485a-ab0e-612c9d175707
Barnes, E.
56e801c0-d2e8-4e5e-87a1-503f5ce70c7e
Brown, A.
4efcbe34-3e7a-4e89-b433-febb9dd81425
Corless, L.
5aa0924d-5268-45e4-aa5d-e10a2a71b955
Cramp, M.
9b98a24f-a1ac-4464-8a58-e60a197e4dd7
Forton, D.
d544e5ae-f8ac-4a3d-8d84-ee8bf41a0e3c
Foster, G.
fbaa7255-7267-4443-a55e-e2a791213022
Foxton, M.
05130ec0-fa39-4643-98d6-13f6248ef98c
Gelson, W.
82d95589-a594-4ce2-af59-a0a9b4568664
Gorard, D.
3e55f9f9-d802-48fa-b014-ade76b051731
Gordon, F.
bd9300ef-64d3-4aaf-bd10-5ae8e37b05d5
Khakoo, S.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Lawson, A.
5c18da3e-b77e-40d1-a79c-110f8f8510c1
McPherson, S.
e5101fdd-1ca4-4864-b603-5ea0a2363f11
Moreea, S.
bd274a23-5629-4d7b-bff0-bf7b96e8333b
Mutimer, D.
9c6f893c-e2e4-483f-9961-6828a91eb509
Prince, M.
b436764c-0f28-4e13-aaa8-2d3cddf5f1f0
Richardson, P.
ea22a3e8-15fd-4e6e-a394-085fa0e15f0d
Rosenberg, W.
145ebec3-ffb6-45e7-8711-aa520ed42f55
Ryder, S.
03484a4b-e3c8-4a95-b63d-5da46ad9cab7
Sreedharan, A.
1f1c705c-b9a5-4f78-8d64-94a4b41635c5
Stone, B.
a1ab8971-003b-4a1e-b01c-73355d1bb807
Ustianowski, A.
d4a18651-7b8a-44a9-a18d-f64a340dac7b
Verma, S.
201a9d04-a18b-41ed-b199-57e2aa18222d
Wiselka, M.
c7a9c751-4e85-4e44-aac5-35de2b848383
HCV Research UK
Johnson, Philip J.
e926deac-dbac-4455-a6ab-57aa8faed6d4
Berhane, Sarah
c01b3772-aacd-4b21-818d-dc4a7cccf7e3
Walker, Alex J.
3dddfe69-6c9c-41a3-a7ca-10287f577312
Gordon, Fiona H.
bf20bbd0-b7ff-4e5e-8948-96b7ecd3d94b
Ryder, Steven D.
ff0ec802-421b-4033-a960-da5fae9c7f45
McPherson, Stuart
cf52d9f4-2bcb-4954-ba16-f12ddc790b45
Sreedharan, Aravamuthan
40600e27-e985-474e-a806-a7e6c0895ade
Ustianowski, Andrew A.
d4a18651-7b8a-44a9-a18d-f64a340dac7b
Agarwal, Kosh
318c0cdd-390b-475d-bf02-323f52b75d7e
Mutimer, David
d67a2cc4-f17d-446d-9167-955177f1c982
Kumada, Takeshi
66bd6e13-4605-430e-9fbd-ae52374587f1
Toyoda, Hidenori
d6ba8630-a837-4554-860b-13f88250b616
Irving, William L.
ed6993df-07a9-4cc1-a859-aa616d644f43
Agarwal, K.
318c0cdd-390b-475d-bf02-323f52b75d7e
Aldersley, M.
72a9c3f4-f70a-477f-82bc-cfb4bf2ae8fe
Ala, A.
6d76aceb-97a9-4581-bc09-7a50a4854aba
Aspinall, R.
455c619f-1968-485a-ab0e-612c9d175707
Barnes, E.
56e801c0-d2e8-4e5e-87a1-503f5ce70c7e
Brown, A.
4efcbe34-3e7a-4e89-b433-febb9dd81425
Corless, L.
5aa0924d-5268-45e4-aa5d-e10a2a71b955
Cramp, M.
9b98a24f-a1ac-4464-8a58-e60a197e4dd7
Forton, D.
d544e5ae-f8ac-4a3d-8d84-ee8bf41a0e3c
Foster, G.
fbaa7255-7267-4443-a55e-e2a791213022
Foxton, M.
05130ec0-fa39-4643-98d6-13f6248ef98c
Gelson, W.
82d95589-a594-4ce2-af59-a0a9b4568664
Gorard, D.
3e55f9f9-d802-48fa-b014-ade76b051731
Gordon, F.
bd9300ef-64d3-4aaf-bd10-5ae8e37b05d5
Khakoo, S.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Lawson, A.
5c18da3e-b77e-40d1-a79c-110f8f8510c1
McPherson, S.
e5101fdd-1ca4-4864-b603-5ea0a2363f11
Moreea, S.
bd274a23-5629-4d7b-bff0-bf7b96e8333b
Mutimer, D.
9c6f893c-e2e4-483f-9961-6828a91eb509
Prince, M.
b436764c-0f28-4e13-aaa8-2d3cddf5f1f0
Richardson, P.
ea22a3e8-15fd-4e6e-a394-085fa0e15f0d
Rosenberg, W.
145ebec3-ffb6-45e7-8711-aa520ed42f55
Ryder, S.
03484a4b-e3c8-4a95-b63d-5da46ad9cab7
Sreedharan, A.
1f1c705c-b9a5-4f78-8d64-94a4b41635c5
Stone, B.
a1ab8971-003b-4a1e-b01c-73355d1bb807
Ustianowski, A.
d4a18651-7b8a-44a9-a18d-f64a340dac7b
Verma, S.
201a9d04-a18b-41ed-b199-57e2aa18222d
Wiselka, M.
c7a9c751-4e85-4e44-aac5-35de2b848383

Johnson, Philip J., Berhane, Sarah, Walker, Alex J., Gordon, Fiona H., Ryder, Steven D., McPherson, Stuart, Sreedharan, Aravamuthan, Ustianowski, Andrew A., Agarwal, Kosh, Mutimer, David, Kumada, Takeshi, Toyoda, Hidenori and Irving, William L. , HCV Research UK (2020) Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 28 (1), 168-176. (doi:10.1111/jvh.13408).

Record type: Article

Abstract

Whilst the benefit of direct-acting antiviral agents (DAAs) in achieving sustained virological response (SVR) is now well-accepted, their impact on liver function, particularly in relation to achievement of SVR, has not been well documented. We studied 2394 patients with chronic HCV infection, 1276 receiving DAAs and 1118 interferon-based therapy. Liver function was assessed by the albumin-bilirubin (ALBI) score or grade. Overall survival according to SVR status and baseline ALBI grade was examined. We also studied time to first decompensation according to ALBI grade, as well as longitudinal changes in ALBI score over time according to SVR. Among the patients receiving DAAs, 89% achieved SVR (Japan = 99%, UK = 78%). Amongst the decompensated patients in the UK cohort, three distinct risk groups according to ALBI grade at baseline were observed. The UK patients receiving DAAs, who had predominantly decompensated disease, showed clear evidence of improvement of liver function detectable within 2 years of the start of treatment, especially in those achieving SVR. These early changes in liver function were very similar to those observed in the first 2-3 years after interferon-based therapy. DAAs improve liver function especially in those with decompensated disease who achieve SVR. Experience with interferon-based therapy suggests that failure to achieve SVR is associated with long-term decline in liver function and, in contrast, patients who do achieve SVR can expect long-term disease improvement and subsequent stabilization of liver function. Our initial analysis suggests that those receiving DAAs are likely, in the long term, to follow a similar course.

Text
Journal of Viral Hepatitis - 2020 - Johnson - Impact of direct‐acting antiviral agents on liver function in patients with - Version of Record
Available under License Creative Commons Attribution.
Download (899kB)

More information

Accepted/In Press date: 17 August 2020
e-pub ahead of print date: 26 September 2020
Published date: 2 November 2020
Keywords: ALBI score, direct-acting antivirals, hepatitis C virus, interferon therapy, liver function, sustained virological response

Identifiers

Local EPrints ID: 484928
URI: http://eprints.soton.ac.uk/id/eprint/484928
ISSN: 1352-0504
PURE UUID: c637bcfb-d81f-4ec6-973c-13a5f2b6fb58
ORCID for G. Foster: ORCID iD orcid.org/0000-0003-3688-9668
ORCID for S. Khakoo: ORCID iD orcid.org/0000-0002-4057-9091

Catalogue record

Date deposited: 24 Nov 2023 17:39
Last modified: 11 May 2024 01:43

Export record

Altmetrics

Contributors

Author: Philip J. Johnson
Author: Sarah Berhane
Author: Alex J. Walker
Author: Fiona H. Gordon
Author: Steven D. Ryder
Author: Stuart McPherson
Author: Aravamuthan Sreedharan
Author: Andrew A. Ustianowski
Author: Kosh Agarwal
Author: David Mutimer
Author: Takeshi Kumada
Author: Hidenori Toyoda
Author: William L. Irving
Author: K. Agarwal
Author: M. Aldersley
Author: A. Ala
Author: R. Aspinall
Author: E. Barnes
Author: A. Brown
Author: L. Corless
Author: M. Cramp
Author: D. Forton
Author: G. Foster ORCID iD
Author: M. Foxton
Author: W. Gelson
Author: D. Gorard
Author: F. Gordon
Author: S. Khakoo ORCID iD
Author: A. Lawson
Author: S. McPherson
Author: S. Moreea
Author: D. Mutimer
Author: M. Prince
Author: P. Richardson
Author: W. Rosenberg
Author: S. Ryder
Author: A. Sreedharan
Author: B. Stone
Author: A. Ustianowski
Author: S. Verma
Author: M. Wiselka
Corporate Author: HCV Research UK

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×